Clinical Trial Detail

NCT ID NCT02382406
Title Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Nisha Mohindra, MD
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST